Global Monoclonal Antibody Market is valued at USD 144.25 Billion in 2020 and expected to reach USD 282.89 Billion by 2027 with a CAGR of 10.1% over the forecast period.
Global Monoclonal Antibodies Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027- Increasing prevalence of cancer & other chronic diseases, growing regulatory approvals & launch of therapies and increasing research collaborations for the development of robust drug pipeline are the major factors driving the growth of global monoclonal antibodies market Over the Forecast Period.
A monoclonal antibody is an immune response made by cloning a remarkable white blood cell. All ensuing antibodies inferred this way trace back to a one of a kind parent cell. Monoclonal antibodies are utilized to develop and suppress the immune response in different medical situations and to treat different sicknesses like cardiovascular, cancer and cerebrovascular infections. This industry incorporates foundations that produce anti-cancer monoclonal antibodies to avoid metastasis by lessening cell expansion, neuropharmacological monoclonal antibodies, immunological monoclonal antibodies, anti-infective monoclonal antibodies (MAbs), and other MAbs for individuals and animals. By exposing white blood cells to a particular antigen, monoclonal antibodies can be created. Monoclonal antibodies are antibodies artificially created in laboratory.
The antibodies which are produced naturally in body will help the immune system recognize microorganisms that cause disease like bacteria and viruses, and mark them for destruction. Like these antibodies, monoclonal antibodies recognize specific targets. Many monoclonal antibodies are used to treat cancer in which targeted cancer therapy, means they are designed to interact with specific targets. They are also used for treatment in Ebola, HIV, and psoriasis. In 1900s, the idea of first delivering antibodies to treat diseases is developed by Noble-prize winning German Immunologist Paul Ehrich, who invented ‘Zauberkugel’ (magic bullet), which selectively targets pathogen.
COVID-19 has shown a positive impact on global monoclonal antibodies market. Research during the pandemic has increased optimism in monoclonal antibodies ability to help reduce the risk of hospitalization. A number of monoclonal antibodies have shown the ability to retain activity against multiple variants of the virus. The advancement of monoclonal antibodies treatment is utilized to treat COVID-19. The acknowledgment of the urgent need for treatment accessible on a worldwide scale has empowered the fast advancement of a vast number of SARS-CoV-2 killing monoclonal antibodies (mAbs). Thus, COVID-19 disease elevated development and opportunities for key participants of monoclonal antibodies during the forecast period.
Some of the key players in monoclonal antibodies are
Global monoclonal antibodies are segmented on the basis of source, indication end user and region & country level. Based upon source, the monoclonal antibodies market is classified into murine, chimeric, humanized, and human. By indication, the market is divided into autoimmune disease, inflammatory disease, infectious disease, cancer and others. Based upon end-users, the market is divided into hospitals, research institutes and others.
The regions covered in global monoclonal antibodies market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of monoclonal antibodies is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India,Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa,etc.
January 21st, 2021; The FDA has approved the utilization of monoclonal antibodies for Covid-19 therapies. Monoclonal antibodies are research center made proteins that copy the immune system's ability to fight off hurtful microorganisms like viruses. Casirivimab and imdevimab are monoclonal antibodies that are particularly coordinated against the spike protein of SARS-CoV-2, intended to obstruct the infection's connection and entry into human cells. Approving these monoclonal antibody treatments might assist outpatients with keeping away from hospitalization and lighten the weight on our medical services system.
One of the major factors driving the growth of global monoclonal antibodies market is increasing prevalence of cancer & other chronic diseases. The cancer risk is rising quickly all through the world and more secure clinical treatment is being searched out over more conventional techniques. Possible advantages of monoclonal antibodies incorporate detecting and killing unusual cells directly, repressing cancer cell development, and conveying radioactive particles or chemo drugs to the particular cells, accordingly limiting the risk of side effects from drug while likewise advancing working of immune system. For instance; according to the World Health Organization; the worldwide cancer trouble increased to 18.1 million new cases and 9.6 million deaths in 2018. One of every five men and one out of six women overall foster cancer throughout their lifetime, and one out of eight men and one out of 11 women die from the illness.
In addition, growing regulatory approvals & launch of therapies are also supplementing the market growth. Increasing number of approvals of monoclonal antibodies by administrative offices favour the dispatch of inventive therapeutics. For example; in 2018, Chugai Pharmaceutical Co., Ltd. (a piece of Roche Holding AG) declared that it got Breakthrough Therapy Designation from the U.S. FDA for its item, Satralizumab. Also, in May 2018, Johnson and Johnson got the U.S. Food and Drug Administration's approval for its monoclonal antibody, Darzalex (daratumumab), in blend with Velcade (bortezomib), melphalan, and prednisone, for the treatment of patients with recently analyzed antibody myeloma, not qualified for autologous stem cell relocate (ASCT).
Furthermore, increasing research collaborations for the development of robust drug pipeline also fostering the growth of global monoclonal antibodies market. For example; in March 2020, the World Health Organization dispatched the 'Solidarity' preliminary, which is a worldwide initiative for testing old and new drugs/treatments for treating Covid-19. The preliminary incorporates testing four treatments; remdesivir, lopinavir and ritonavir, chloroquine and hydroxychloroquine, lopinavir with ritonavir and interferon-beta.
However, high cost and strict regulatory measures resulting in lengthy approval procedure may hamper the market growth. In spite of that, growing public investments for cancer research and technological development can provide various opportunities for the further growth of the global monoclonal antibodies market.
North America is expected to dominate the global monoclonal antibodies market due to the rising funding by government to increase research and development activities for cancer, rising number of product launches, regulatory support for rare diseases and presence of key players in this region. For instance; as indicated by the Centers for Disease Control and Prevention (CDC); six out of 10 grown-ups in the U.S. have a chronic disease, of which four of every 10 Adults have at least two. For example; the U.S. Food and Drug Administration (FDA) conceded sped up endorsement to avelumab, a human monoclonal antibody, for the treatment of an uncommon infection metastatic Merkel cell carcinoma (MCC). Essentially, the U.S FDA allowed sped up approval to immunotherapy item TECENTRIQ (atezolizumab), an acculturated, designed monoclonal antibody, to treat individuals with privately progressed or metastatic urothelial carcinoma. In February 2019, AbCellera and Novartis have done a multi-target association to make an antibody-drug disclosure stage and innovation for treating clinically- relevant and neurodegenerative sicknesses.
Asia-Pacific is expected to show a significant growth in the market due to the rising prevalence of cancer and increasing funding in research and development activities in this field in this region. For instance; according to GLOBOCAN, in 2018, an expected 43.6% new instance of breast cancer was enrolled in Asia Pacific. Europe is expected grow significantly due to the increase in spending capacity of people along and also growing awareness among the patients.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 144.25 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||USD 282.89 Billion|
|Tables, Charts & Figures:||175|
|Monoclonal Antibodies Manufacturers||Abbott Laboratories, Amgen Inc, AstraZeneca plc, Bayer AG, Eli Lilly, GlaxoSmithKline Plc, Johnson &Johnson, Merck&Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A., F. Hoffmann-La Roche AG, and others.|
|Segments Covered||By Source, By Indication, By End User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
Kemp House, 152 - 160 City Road, London EC1V 2NX
© Copyright 2022-23 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®